South Africa: Consolidated Regulations
You are here: SAFLII >> Databases >> South Africa: Consolidated Regulations >> REGULATIONS FOR HAZARDOUS BIOLOGICAL AGENTS | NoteupREGULATIONS FOR HAZARDOUS BIOLOGICAL AGENTS
Download original files |

Last checked: 9 October 2019
OCCUPATIONAL HEALTH AND SAFETY ACT
Act 85 of 1993.
REGULATIONS FOR HAZARDOUS BIOLOGICAL
AGENTS
[Updated to 27 December 2001]
GoN R1390, G. 22956 (c.i.o 27 December 2001).
The Minister of Labour has under section 43 of the Occupational Health and
Safety Act, 1993 (Act 85 of 1993) on the recommendation
of the Advisory Council
for Occupational Health and Safety, made the regulations in the
Schedule.
ARRANGMENT OF REGULATIONS
- Definitions
- Scope of application
- Classification of biological agents
- Information and training
- Duties of persons who might be exposed to HBA
- Risk assessment by employer or self-employed person
- Monitoring exposure at workplace
- Medical surveillance
- Records
- Control of exposure to HBA
- Personal protective equipment and facilities
- Maintenance of control measures, equipment and facilities
- Prohibitions
- Labelling, packaging, transporting and storage
- Special measures for health and veterinary isolation facilities
- Special measures for laboratories, animal rooms and industrial processes
- Disposal of HBA
- Offences and penalties
- Short title
Annexure A
Annexure B
Annexure D
Annexure
E
Annexure F
ARRANGEMENT OF REGULATIONS
- Definitions
In these Regulations any word or expression to which a meaning has been assigned in the Act shall have the meaning so assigned and, unless the context indicates otherwise—
“biological agent” means any micro-organism, cell culture or human endoparasite, including any which have been genetically modified, which may cause an infection, allergy or toxicity, or otherwise create a hazard to human health;
“decontamination” means to remove, as far as is reasonably practicable, all inanimate objects by way of sweeping, cleaning, washing, ventilating or any other process aimed at removing the contaminant;
“diagnostic laboratory” means a workplace where diagnostic or other screening procedures are performed on blood or other potentially infectious materials;
“disinfect” means to render non-viable virtually all recognised pathogenic micro-organisms, but not necessarily all microbial forms;
“engineering control measures” means control measures that remove or reduce the exposure of persons at the workplace by means of engineering methods;
“Facilities Regulations” means the Facilities Regulations promulgated by Government Notice R.2362 of 5 October 1990 under section 43 of the Act;
“General Administrative Regulations” means the General Administrative Regulations promulgated by Government Notice R.1449 of 6 September 1996 under section 43 of the Act;
“HBA” means hazardous biological agents which are
micro-organisms, including those that have been genetically modified, pathogens,
cells,
cell cultures and human endoparasites that have the potential to provoke
an infection toxic effects, subdivided into the following
groups—
(a) Group 1 HBA are HBA that is unlikely to cause human disease;
(b) Group 2 HBA are HBA that may cause human disease and be a hazard to exposed persons, which is unlikely to spread to the community and for which effective prophylaxis and treatment is usually available;
(c) Group 3 HBA are HBA that may cause severe human disease, which presents a serious hazard to exposed persons and which may present a risk of spreading to the community, but for which effective prophylaxis and treatment is available;
(d) Group 4 HBA are HBA that causes severe human disease and is a serious
hazard to exposed persons and which may present a high risk
of spreading to the
community, but for which no effective prophylaxis and treatment is
available;
“micro-organisms” means microbiological entities, cellular or non-cellular, capable of replication or of transferring genetic material;
“monitoring” means the planning and carrying out of the measurement programme and the recording of the results thereof;
“respiratory protective equipment” means a device which is worn over at least the mouth and nose to prevent the inhalation of airborne hazardous biological agents, and which conforms to a standard, acceptable to the chief inspector;
“safety equipment” means a contrivance or a device designed to as far as possible try and prevent injury;
“standard precautions” means a synthesis of the major
features of Universal Precautions (UP) and Body Substance Isolation (BSI) and
applies to all persons
coming into contact with potentially infected persons,
animals or animal products and potentially contaminated blood and other body
fluids in health care facilities or elsewhere and—
(a) apply to—
(i) all blood;
(ii) all body fluids, secretions and excretions, except sweat, regardless of whether they contain visible blood or not;
(iii) non-intact skin;
(iv) mucous membranes; and
(v) tissues; and
(b) are designed to reduce the risk of transmission of HBA from both
recognised and unrecognised sources of infection in workplaces;
“the Act” means the Occupational Health and Safety Act,
1993 (Act 85 of 1993).
- Scope of application
(1) Subject to subregulation (2), these Regulations shall apply to every
employer and self-employed person at a workplace where—
(a) HBA is deliberately produced, processed, used, handled, stored or transported; or
(b) an incident, for which an indicative list is given in Annexure A to these
Regulations occurs that does not involve a deliberate
intention to work with an
HBA but may result in persons being exposed to HBA in the performance of his or
her work.
(2) Regulations 8, 14, 15, 16 and 17 shall not apply to an employer or
self-employed person at a workplace where the exposure is restricted
to a Group
1 HBA.
- Classification of biological agents
(1) The chief inspector may publish in the Government Gazette for the purpose of these regulations a document, which may be revised or reissued from time to time, entitled “Categorisation of Biological Agents according to hazard and categories of containment” (Annexure B) to these Regulation containing a list of biological agents together with the classification of each agent.
(2) Where a biological agent has not been assigned a classification, the employer and self-employed person shall provisionally classify that agent in accordance with subregulation (3) below, having regard to the nature of the agent and the properties of which he or she may reasonably be expected to be aware.
(3) When provisionally classifying a biological agent, the employer and
self-employed person shall assign that agent to one of the
groups and if there
is according to its level of risk of infection doubt as to which of two
alternative groups would be most appropriate,
the HBA shall be assigned to the
higher of the two.
- Information and training
(1) An employer shall, before any employee is exposed or may be exposed to
HBA and after consultation with the health and safety committee
established for
that section of the workplace, ensure that the employee is adequately and
comprehensively informed and trained, on
both practical aspects and theoretical
knowledge with regard to—
(a) the contents and scope of these Regulations;
(b) the potential risks to health caused by the exposure;
(c) the measures to be taken by the employer to protect an employee against any risk of being exposed;
(d) the importance of good housekeeping at the workplace and personal hygiene requirements;
(e) the precautions to be taken by an employee to protect him- or herself against the health risks associated with the exposure, including the wearing and use of protective clothing and respiratory protective equipment;
(f) the necessity, correct use, maintenance and potential of safety equipment, facilities and engineering control measures provided;
(g) the necessity of medical surveillance;
(h) the safe working procedures regarding the use, handling, storage, labelling, and disposal of HBA at the workplace;
(i) the procedures to be followed in the event of exposure, spillage, leakage, injury or any similar emergency situation, and decontaminating or disinfecting contaminated areas; and
(j) the potential detrimental effect of exposure on the human reproductive process.
(2) An employer or a self-employed person shall give instructions in writing of the procedures contemplated in subregulation (1)(i) to the drivers of vehicles carrying the HBA.
(3) Every employer and every self-employed person shall ensure that he or she
or any person who in any manner assists him or her in
the carrying out or
conducting of his or her business has the necessary information and has
undergone sufficient training in order
for him or her to identify the potential
risks and the precautions that should be taken.
- Duties of persons who might be exposed to HBA
(1) Any person who is or might be exposed to HBA, shall obey any lawful
instruction given by or on behalf of the employer of a self-employed
person
regarding—
(a) the prevention of an uncontrolled release of an HBA;
(b) the adherence to instructions regarding environmental and health practices, personal hygiene and good housekeeping;
(c) the wearing of personal protective equipment and clothing as prescribed
by these Regulations;
(d) the wearing of personal samplers, when necessary, to measure personal exposure to airborne hazardous biological substances;
(e) the disposal of materials containing HBA and the disinfection and decontamination of any site contaminated by an HBA;
(f) the reporting during normal working hours for such medical examination or test as contemplated in regulation 8(1); and
(g) information and training as contemplated in regulation 4.
(2) Any person shall immediately report to the employer, the health and
safety representative or self-employed person any possible
accidental exposure
to an HBA at the workplace, and the employer or self-employed person shall
ensure that such incident is investigated
and recorded in accordance with
regulation 8 of the General Administrative Regulations.
- Risk assessment by employer or self-employed person
(1) An employer or a self-employed person contemplated in regulation 2 shall, after consultation with the relevant health and safety representative or relevant health and safety committee, cause a risk assessment to be made and thereafter at intervals not exceeding two years, to determine if any person might have been exposed to an HBA.
(2) An employer shall inform the relevant health and safety representative or health and safety committee in writing of the arrangements made for the assessment contemplated in subregulation (1), give them reasonable time to comment thereon and ensure that the results of the assessment are made available to the relevant health and safety representative or health and safety committee, which may comment thereon.
(3) When making the assessment, the employer or self-employed person shall
keep a record of the assessment and take into account matters
such
as—
(a) the nature and dose of the HBA to which an employee may be exposed and the suspected route of exposure;
(b) where the HBA might be present and in what physical form it is likely to
be;
(c) the nature of the work, process and any reasonable deterioration in, or failure of, any control measures;
(d) what effects the HBA can have on an employee; and
(e) the period of exposure.
(4) An employer or a self-employed person shall cause the risk assessment to
be conducted on the basis of all available information
as far as is reasonably
practicable, including—
(a) classification of the HBA into the relevant risk group, according to its level of risk of infection;
(b) recommendations from the manufacturer, supplier or a competent person regarding the control measures necessary in order to protect the health of persons against such agents as a result of their work;
(c) information on diseases that may be contracted as a result of the activities at the workplace;
(d) potential allergenic or toxic effects that may result from the activities
at the workplace; and
(e) knowledge of diseases from which an employee might be suffering and which
may be aggravated by conditions at the workplace.
(5) An employer shall review the assessment required by subregulation (1)
forthwith if there—
(a) is a reason to suspect that the previous assessment is no longer valid; or
(b) has been a change in a process involving an HBA or in the methods,
equipment or procedures in the use, handling, control or processing
of HBA, and
the provisions of subregulations (2), (3) and (4) shall apply.
- Monitoring exposure at workplace
An employer shall ensure that the exposure of employees to an HBA is
monitored in accordance with a suitable procedure that is standardised,
sufficiently sensitive and of proven effectiveness in any case which it
is—
(a) requisite for ensuring the maintenance of adequate control of the exposure of employees to HBA; or
(b) otherwise requisite for protecting the health of employees.
- Medical surveillance
(1) An employer shall ensure that an employee is under medical surveillance
if—
(a) the results of the assessment referred to in regulation 6 indicate that an employee might have been exposed to HBA;
(b) the exposure of the employee to any HBA hazardous to his or her health is such that an identifiable disease or adverse effect to his or her health may be related to the exposure, there is a reasonable likelihood that the disease or effect may occur under the particular conditions of his or her work and there are techniques such as pre-clinical biomarkers where appropriate for detecting sensitisation to allergens or an inflammatory response associated with exposure to diagnose indications of the disease or the effect as far as is reasonably practicable; or
(c) an occupational health practitioner recommends that the relevant employee
should be under medical surveillance, in which case
the employer may call upon
an occupational medicine practitioner to ratify the appropriateness of such
recommendation.
(2) In order to comply with the provisions of subregulation (1), the employer
shall after extensive counselling and education offer
the employee the
opportunity to have—
(a) an initial health evaluation, which should be carried out by an
occupational health practitioner immediately before or within
14 days after a
person commences employment, where any exposure exists or might exist, which
comprises—
(i) an evaluation of the employee’s medical and occupational history;
(ii) a physical examination; and
(iii) any biological tests and other appropriate medical tests or any other
essential examination that in the opinion of the occupational
health
practitioner is desirable in order to enable the practitioner to do a proper
evaluation;
(b) periodic medical examinations and tests in cases where an HBA is known to
be capable of causing persistent or latent infections
which—
(i) in the light of present knowledge, are undiagnosable, until signs or symptoms develop;
(ii) can have particularly long incubation periods;
(iii) can result in an illness which is recurrent in spite of treatment; and
(iv) are known to have serious long-term effects.
(c) All tests and examinations as contemplated in paragraphs (a) and (b)
shall be conducted according to a written medical protocol.
(3) The employer shall, in accordance with regulation 8 of the General Administrative Regulations, investigate and record all incidents that result or might result in infections or the death of an employee.
(4) All occupational health practitioners shall submit to the health and
safety committee for approval a written protocol for procedures
to be followed
when dealing with abnormal results.
- Records
(1) An employer shall—
(a) keep records of all assessments, monitoring results and medical surveillance reports required by regulations 6, 7 and 8 respectively: Provided that personal medical records shall be made available only to an occupational health practitioner;
(b) subject to the provisions of paragraph (c), make the records contemplated in paragraph (a), excluding personal medical records, available for inspection by an inspector;
(c) subject to the formal written consent of an employee, allow any person to peruse the records with respect to that particular employee;
(d) make the records of all risk assessments and monitoring results available for perusal by the health and safety representative or health and safety committee;
(e) keep all records of risk assessments and monitoring results for a minimum
period of 40 years;
(f) keep all medical surveillance records for a minimum period of 40 years, and if the employer ceases activities, all those records shall be handed over or forwarded by registered post to the relevant provincial director; and
(g) keep a record of the examinations and tests carried out in terms of
regulation 12(b) and of any repairs resulting from these investigations
and
tests, which records shall be kept for at least three years.
(2) A self-employed person shall keep records of all risk assessments for a
minimum period of 40 years, and if the self-employed person
ceases activities,
all those records shall be handed over or forwarded by registered post to the
relevant provincial director.
- Control of exposure to HBA
(1) An employer and self-employed person shall ensure that the—
(a) exposure of persons to HBA in the working environment is either prevented or, where this is not reasonably practicable, adequately controlled; and
(b) standard precautions contained in Annexure C to these Regulations are
implemented to reduce the risk of transmission of HBA from
recognised and
unrecognised sources of infection in a workplace.
(2) Where reasonably practicable, the employer or self-employed person shall
control the exposure of persons to an HBA in the working
environment by applying
the following measures where appropriate—
(a) Limiting the amount of HBA used which might contaminate the working environment;
(b) limiting the number of employees who will be exposed or might be exposed;
(c) introducing engineering control measures for the control of exposure,
which may include the following—
(i) Process separation, automation or enclosure;
(ii) the installation of local extraction ventilation systems to processes,
equipment and tools for the control of emissions of an
airborne HBA;
(iii) separate workplaces for different processes;
(iv) proper access control to prevent unauthorised access; and
(v) immediate personal or environmental disinfection;
(d) introducing appropriate work procedures that employees must follow where
materials are used, processes are carried out, or incidents
might occur that
could give rise to the exposure of an employee to HBA, and such procedures shall
include written instructions to
ensure—
(i) the safe handling, use and disposal of HBA;
(ii) the proper use and maintenance of process machinery, installations, equipment, tools and local extraction and general ventilation systems;
(iii) the regular cleaning of machinery and work areas by vacuum cleaners fitted with a suitable filter that prevents contamination of the environment; and
(iv) that a system whereby changes in work procedures and processes that
indicate the need for early corrective action can be readily
identified;
(e) ensuring that emissions to the atmosphere comply with the provisions of the Atmospheric Pollution Prevention Act, 1965 (Act 45 of 1965);
(f) displaying the biohazard sign shown in Annexure D to these Regulations and other relevant warning signs; and
(g) specifying procedures for taking, handling and processing samples that
might contain HBA.
- Personal protective equipment and facilities
(1) If it is not reasonably practicable to ensure that the exposure of an
employee is adequately controlled as contemplated in regulation
10, the employer
shall in the case of—
(a) airborne HBA, provide the employee with suitable respiratory protective equipment and protective clothing; and
(b) HBA that can be absorbed through the skin, provide the employee with
suitable impermeable personal protective equipment.
(2) Where respiratory protective equipment is provided, the employer shall
ensure that—
(a) the relevant equipment is capable of preventing the exposure to the HBA concerned;
(b) the relevant equipment is correctly selected and properly used;
(c) information, instructions, training and supervision which would be necessary with regard to the use of the equipment are known to the employees; and
(d) the equipment is kept in good condition and efficient working
order.
(3) An employer shall as far as is reasonably practicable—
(a) not issue personal protective equipment which has been used to an employee, unless it is capable of being decontaminated and sterilised prior to use;
(b) provide separate containers or storage facilities for personal protective equipment and protective clothing when not in use; and
(c) take steps to ensure that all protective equipment and protective
clothing not in use are stored in a demarcated area with proper
access
control.
(4) An employer shall as far as is reasonably practicable, ensure that all
contaminated personal protective clothing issued is cleaned
and handled in
accordance with the following procedures—
(a) Where such clothing is cleaned on the premises of the employer, care shall be taken to prevent contamination during handling, transporting and cleaning;
(b) where the clothing is sent off the premises to a contractor for cleaning purposes, the clothing shall be placed in impermeable, tightly sealed colour coded containers and such containers shall be clearly identified with a biohazard label as depicted in Annexure D to these Regulations as contaminated; and
(c) ensure that the contractor as contemplated in subregulation (4)(b) is
fully informed of the requirements of these Regulations
and the precautions to
be taken regarding the handling of contaminated clothing.
(5) Subject to the provisions of subregulation (4)(b), an employer shall ensure that no person removes dirty or contaminated personal protective equipment and personal protective clothing from the premises: Provided that where contaminated personal protective equipment has to be disposed of, it shall be treated as HBA waste as contemplated in regulation 17.
(6) Subject to the provisions of the Facilities Regulations an employer
shall, where reasonably practicable, provide employees using
personal protective
equipment and clothing as contemplated in subregulation (1) with—
(a) adequate washing facilities which are readily accessible and located in an area where the facilities will not become contaminated, in order to enable the employees to meet the standard of personal hygiene consistent with the adequate control of exposure, and to avoid the spread of HBA;
(b) two separate lockers labelled “protective clothing” and “personal clothing”, respectively, and ensure that the clothing is kept separately in the locker concerned; and
(c) separate “clean” and “dirty” change rooms if the
employer uses or processes HBA to the extent that the
HBA could endanger the
health of persons outside the workplace.
- Maintenance of control measures, equipment and facilities
An employer shall ensure that—
(a) all control measures, equipment and facilities provided in terms of regulations 10 and 11 are maintained in good working order; and
(b) thorough examinations and tests of engineering control measures are
carried out at intervals not exceeding 24 months by an approved
HBA inspection
authority or by a person whose ability to do the measurements, analysis and
tests is verified by such an approved
HBA inspection authority.
- Prohibitions
(1) No person shall—
(a) use compressed air to remove HBA from any surface or person;
(b) eat, drink, smoke, keep food or beverages or apply cosmetics in an HBA, workplace or require or permit any other person to eat, drink, smoke, keep food or beverages or apply cosmetics in such a workplace; or
(c) leave a controlled area without prior removal of protective or
contaminated clothing and equipment.
(2) An employer or self-employed person shall cause a notice to be posted at
a conspicuous place prohibiting the provision of (a),
(b) and (c).
- Labelling, packaging, transporting and storage
An employer or self-employed person shall, as far as is reasonably practicable, take steps to ensure that—
(a) all HBA under his or her control in storage, transit or being distributed, are properly contained and controlled to prevent the spread of contamination from the workplace;
(b) the colour coded containers in which HBA are transported are clearly marked with a bio-hazard sign as depicted in Annexure D to these Regulation and other relevant warning signs that identify the contents; and
(c) the driver is trained in and equipped with a certificate in emergency
procedures.
- Special measures for health and veterinary isolation facilities
(1) Subject to the provisions of regulation 6, every employer and
self-employed person shall, in the case of health and veterinary
isolation
facilities, take into account—
(a) uncertainties about the presence of HBA in a patient or animal and the materials and specimens taken from them;
(b) the hazard represented by HBA known or suspected to be present in a patient, animal, materials and specimens taken from them; and
(c) the risks posed by the nature of the work.
(2) An employer or self-employed person as contemplated in subregulation (1)
shall ensure that the correct containment measures as
indicated in Annexures C
and E to these Regulations are selected for persons and animals in
isolation facilities that are suspected of being infected with Group 3 or Group
4 HBA in order
to minimise the risk of infecting others.
- Special measures for laboratories, animal rooms and industrial processes
In the case of laboratories, animal rooms and industrial processes the
employer or self-employed person contemplated in regulation
2 shall ensure that
the containment measures required in—
(a) Annexure C and E are implemented in laboratories and in rooms for laboratory animals, including diagnostic laboratories, and in rooms for laboratory animals that have been deliberately infected with Group 2, 3 and 4 HBA or where laboratory animals are suspected of carrying such agents;
(b) Annexure C and E are implemented in laboratories handling materials in respect of which uncertainty prevails about the presence of HBA that may cause human disease, but that do not have as their aim working with HBA as such: Provided that the containment measures that are required for Group 3 or 4 are implemented where it is known or suspected that it is necessary; and
(c) Annexure C and F are implemented where Group 2, 3 or 4 HBA are used in
industrial processes: Provided that where it has not been
possible to carry out
a conclusive assessment of HBA, but where the use envisaged might involve a
serious health risk for persons,
such activities may be carried out only in
workplaces where the containment measures correspond to the requirement for
Group 3 HBA.
- Disposal of HBA
An employer or self-employed person as contemplated in regulation 2
shall—
(a) lay down written procedures for appropriate decontamination and disinfection;
(b) implement written procedures enabling infectious waste to be handled and disposed of without risk;
(c) ensure that all fixtures and equipment including vehicles, re-usable
containers and covers which have been in contact with HBA
waste are disinfected
and decontaminated after use in such a manner that it does not cause a hazard
inside or outside the premises
concerned;
(d) ensure that all HBA waste that can cause exposure is disposed of only on sites specifically designated for this purpose in terms of the Environmental Conservation Act, 1989 (Act 73 of 1989), in such a manner that it does not cause a hazard inside or outside the site concerned;
(e) ensure that all employees involved in the collection, transport and disposal of HBA waste and who may be exposed to that waste are provided with suitable personal protective equipment; and
(f) ensure that if the services of a waste disposal contractor is used, a
provision is incorporated into the contract stating that
the contractor shall
comply with the provisions of these Regulations.
- Offences and penalties
Any person who contravenes or fails to comply with any provisions of
regulation 3 to 17 shall be guilty of an offence and liable on
conviction to a
fine or to imprisonment for a period not exceeding 12 months and, in the case of
a continuous offence, to an additional
fine of R200 for each day on which the
offence continues or additional imprisonment of one day for each day on which
the offence
continues: Provided that the period of such additional imprisonment
shall in no case exceed 90 days.
- Short title
These Regulations shall be called Regulations for Hazardous Biological
Agents.
ANNEXURE A
INDICATIVE LIST OF
INCIDENTS
(Regulation 2(1)(b))
Incidents or exposure during work—
(a) in a food production plant;
(b) where there is contact with animals or products of animal origin;
(c) in health care, including isolation and post-mortem units;
(d) in clinical, veterinary and diagnostic laboratories;
(e) in sewage purification installations; and
(f) in a general workplace.
ANNEXURE B
HAZARDOUS BIOLOGICAL AGENTS
GUIDELINES
CATEGORISATION OF BIOLOGICAL AGENTS ACCORDING TO HAZARD
AND CATEGORIES OF CONTAINMENT:
INTRODUCTION
- The attached list must be read in conjunction with the Hazardous Biological Agents, and in particular regulation 3.
- Agents listed are categorised on the basis of their ability to cause disease by infection.
- In allocating agents to a hazard Group in the list no account is taken of particular effects on those whose susceptibility to infection may be affected for one or other reason such as pre-existing disease, medication, compromised immunity, pregnancy or breastfeeding. Additional risk to such workers should be considered as part of the assessment required by the Hazardous Biological Agents.
- Biological agents that have not been classified for inclusion into Group 2 to 4 in the list are not implicitly classified in Group 1.
- If more than one species of any particular agent is known to be pathogenic to humans, the most prominent of these is generally named, together with the wider reference ‘species’ (spp) to indicate the fact that the other species of the same genus may be hazardous. If a whole genus is mentioned in this way, it is implicit that species and strains that are non-pathogenic to humans are excluded.
- When a strain is attenuated or has lost known virulence genes, the containment required by the classification of its parent strain need not necessarily apply, subject to assessment appropriate to the risk in the workplace, for example when such strain is used as a product or as part of a product for prophylactic or therapeutic purposes. (See 2)
- All viruses that have been isolated in humans and that have not been assessed and allocated to a Group in the list are to be classified in Group 2 as a minimum, except where there is evidence that they are unlikely to cause disease in humans.
- The requirements as to containment consequent upon the classification of parasites apply only to stages in the life cycle of the parasite in which it is liable to be infectious for humans.
- The list also gives a separate indication where biological agents are capable of causing allergic or toxic reactions, where an effective vaccine is available.
The following notations identify the indications—
A: Possible allergic effects;
T: Toxin production;
V: Effective vaccine available;
NIV: National Institute of Virology.
The selection of control measures for biological agents should take into account the fact that there are no exposure limits for them. Their ability to replicate and to infect at very small doses means that exposure may have to be reduced to levels that are diminishingly low.
For each activity the first consideration should be whether it could be carried out in a way that involves exposure to a less harmful biological agent. This may be practicable, for example, in teaching and some types of research. If there is more than one way of carrying out the activity then the method carrying the least risk should be chosen.
If the least harmful alternative still involves exposure or potential
exposure to biological agent, or the nature of the activity
is such that there
is no choice, and it is not reasonably practicable to prevent exposure by some
other means, then exposure should
be adequately controlled. All of the measures
listed in Annexure E should be considered, and each should be used where and to
the
extent that—
(a) it is applicable; and
(b) the assessment carried but under regulation 6 shows that it will lead to
a non-negligible reduction in risk.
Not all the listed measures will be required in every case. The assessment may indicate, for example, that a specific mode of transmission and route of infection is required, a susceptible host is needed, there is low prevalence of the infection in that particular activity, and that illness is easily treatable, leading to rapid and complete recovery.
In such a case the risk would be relatively low and the control measures required less stringent. Another factor that will determine whether controls are to be applied will be the extent to which the activity involves the handling or deliberate use of a biological agent, or exposure is incidental to the main purpose of the work. However, the level of risk should be the principal consideration if the risk is sufficiently high and can be reduced by some of the listed measures, they should be applied in full.
Certain special measures are required in health and veterinary care
facilities, laboratories, animal rooms and industrial processes
to ensure that
biological agents are not transmitted to workers or outside the controlled area.
For laboratories, animal rooms and
industrial processes rules are laid down for
the derivation of containment level from the hazard classification of the agent,
or
from what is suspected about the possible presence of an agent. Laboratories
screening for an agent which falls in Group 3 and 4,
but which is not ordinarily
expected to be present (for example a microbiological laboratory in a food
factory screening for salmonella,
with the possibility of finding Salmonella
typhi), should achieve at least containment level 2, but switch to the
appropriate higher level if the agent is found and if work is to
continue with
it. In a laboratory that does not deliberately work with biological agents, but
where the presence of agents calling
for containment levels 3 or 4 is
nevertheless known or suspected, those containment levels should be
used.
Agents with reduced virulence may be used at a lower than normal level of containment if the alteration has effectively changed their classification.
A biological agent that falls or is treated as falling into Hazard Group 1
may be a Group 3 genetically modified organism, because
of environmental risks
associated with it or because, though now unlikely to cause human disease, it is
derived by genetic modification
from a pathogenic parental organism. In the
latter case, the selection of containment measures appropriate to the
agent’s reduced
virulence and corresponding group may be permitted. Where
there is a mismatch, as in the case of a genetically modified organism
or
biological agent which is non-hazardous to humans, but environmentally harmful,
more stringent requirements should be followed.
Where the rules as set out lead to a particular containment level for an activity, all the measures appropriate to that level should normally be used. Some selection may be done, however, to suit individual circumstances, provided that the risk is not increased by doing so.
Regulation 11 sets out additional requirements in respect of personal protective equipment used to protect employees against biological agents. The object of these requirements is to prevent the equipment itself from acting as the means by which agents are transmitted, and they should be followed accordingly.
Where workers are exposed to biological agents the information and instructions given to them, if applicable, should be set down in the form of written instructions, outlining procedures to be followed after a serious incident involving the handling of a biological agent as well as the procedure for handling any Group 4 agent.
If the nature of the workplace and the activity are such that employees may
need instant access to this information, or where a reduction
in risk may be
expected by having the information conspicuously displayed in the workplace, it
should also be set out on notices
displayed in the
workplace.
BACTERIA
Key:
A: allergic effects
T: Toxic effects
V: Vaccine available
NIV: National Institute of Virology
Biological Agent
|
Classification
|
Notes
|
Acinetobacter calcoaceticus
|
2
|
|
Acinetobacter Iwoffi
|
2
|
|
Actinobacllus actinomycetem comitans
|
2
|
|
Actinomadura madurae
|
2
|
|
Actinomadura pelletieri
|
2
|
|
Actinomyces spp
|
2
|
|
Aeromonas hydrophila
|
2
|
|
Alcaligenes spp
|
2
|
|
Arcanobacterium haemolyticum
(Corynebacterium haemolyticum) |
2 |
|
Arizona spp
|
2
|
|
Bacillus anthracis
|
3
|
V
|
Bacillus cereus
|
2
|
|
Bacteroides spp
|
2
|
|
Bartonella spp
(Rochalimaea spp) |
2 |
|
Bordetella bronchiseptica
|
2
|
|
Bordetella parapertussis
|
2
|
|
Bordetella pertussis
|
2
|
V
|
Borrelia burgdoferi
|
2
|
|
Borrelia spp
|
2
|
|
Brucella spp
|
3
|
|
Burkholderia cepacia
|
2
|
|
Burkholderia mallei
(Pseudomonas mallei) |
3 |
|
Burkholderia pseudomallei
(Pseudomonas pseudomallei) |
3 |
|
Burkholderia spp
|
2
|
|
Campylobacter spp
|
2
|
|
Cardiobacterium hominis
|
2
|
|
Chlamydia pneumoniae
|
2
|
|
Chlamydia psittaci
(non-avian strains) |
2 |
|
Chlamydia psittaci
(avian strains) |
3 |
|
Chlamydia trachomatis
|
2
|
|
Clostridium botulinum
|
2
|
T,V
|
Clostridium perfringens
|
2
|
|
Clostridium tetani
|
2
|
T,V
|
Clostridium spp
|
2
|
|
Corynebacterium diphtheriae
|
2
|
T,V
|
Corynebacterium minutissimum
|
2
|
|
Corynebacterium pseudo-tuberculosis
|
2
|
|
Corynebacterium spp
|
2
|
|
Coxiella burnetii
|
3
|
|
Edwardsiella tarda
|
2
|
|
Ehrlichia sennetsu
(Rickettsia sennetsu) |
3 |
|
Ehrlichia spp
|
3
|
|
Eikenella corrodens
|
2
|
|
Enterobacter spp
|
2
|
|
Enterococcus spp
|
2
|
|
Erysipelothrix rhusiopathiae
|
2
|
|
Escherichia coli
(with the exception of non-pathogenic strains |
2 |
|
Flavobacterium meningosepticum
|
2
|
|
Fluorobacter bozemanae
(formerly Legionella) |
2 |
|
Francisella tularensis (type A)
|
3
|
V
|
Francisella tularensis (Type B)
|
2
|
|
Fusobacterium spp
|
2
|
|
Gardnerella vaginalis
|
2
|
|
Haemophilus ducreyi
|
2
|
|
Haemophilus influenzae
|
2
|
|
Haemophilus spp
|
2
|
|
Helicobacter pylori
|
2
|
|
Klebsiella oxytoca
|
2
|
|
Klebsiella pneumoniae
|
2
|
|
Klebsiella spp
|
2
|
|
Legionella pneumophila
|
2
|
|
Legionella spp
|
2
|
|
Leptospira interrogans (all serovars)
|
2
|
|
Listeria ivanovii
|
2
|
|
Listeria monocytogenes
|
2
|
|
Moraxella catarrhalis
|
2
|
|
Moraxella lacunata
|
2
|
|
Morganella morganii
|
2
|
|
Mycobacterium africanum
|
3
|
V
|
Mycobacterium avium / intracellulare
|
3
|
|
Mycobacterium bovis (BCG strain)
|
2
|
|
Mycobacterium bovis
|
3
|
V
|
Mycobacterium chelonae
|
2
|
|
Mycobacterium fortuitum
|
2
|
|
Mycobacterium kansasii
|
3
|
|
Mycobacterium leprae
|
3
|
V
|
Mycobacterium malmoense
|
3
|
|
Mycobacterium marinum
|
2
|
|
Mycobacterium microti
|
3
|
|
Mycobacterium paratuberculosis
|
2
|
|
Mycobacterium scrofulaceum
|
3
|
|
Mycobacterium szulgai
|
3
|
|
Mycobacterium simiae
|
3
|
|
Mycobacterium tuberculosis
|
3
|
V
|
Mycobacterium ulcerans
|
3
|
|
Mycobacterium xenopi
|
3
|
|
Mycoplasma hominis
|
2
|
|
Mycoplasma pneumoniae
|
2
|
|
Neisseria gonorrhoeae
|
2
|
|
Neisseria meningitidis
|
2
|
V
|
Nocardia spp
|
2
|
|
Pasteurella spp
|
2
|
|
Peptrostreptococcus spp
|
2
|
|
Plesiomonas shigelloides
|
2
|
|
Porphyromonas spp
|
2
|
|
Prevotella spp
|
2
|
|
Proteus mirabilis
|
2
|
|
Proteus penneri
|
2
|
|
Proteus vulgaris
|
2
|
|
Providencia spp
|
2
|
|
Pseudomonas aeruginosa
|
2
|
|
Pseudomonas mallei
- see Burkholderia mallei |
3 |
|
Pseudomonas pseudomallei
- see Burkholderia pseudomallei |
3 |
|
Rhodococcus equi
|
2
|
|
Rickettsia spp
|
3
|
|
Rochalimaea quintana
- see Bartonella spp |
2 |
|
Rochalimaea spp
- see Bartonella spp |
2 |
|
Salmonella arizonae
|
2
|
|
Salmonella enteritidis
|
2
|
|
Salmonella (other serovars)
|
2
|
|
Salmonella paratyphi A, B, C
|
2
|
|
Salmonella typhi
|
3
|
V
|
Salmonella typhimurium
|
2
|
|
Serpulina spp
|
2
|
|
Serratia liquefaciens
|
2
|
|
Serratia marcescens
|
2
|
|
Shigella boydii
|
2
|
|
Shigella dysenteriae (Type 1)
|
3
|
T
|
Shigella dysenteriae (other than Type 1)
|
2
|
|
Shigella flexneri
|
2
|
|
Shigella sonnei
|
2
|
|
Staphylococcus aureus
|
2
|
T
|
Stenotrophomonas maltophilia
|
2
|
|
Strepobacillus moniliformis
|
2
|
|
Streptococcus spp
|
2
|
|
Treponema spp
|
2
|
|
Ureaplasma urealyticum
|
2
|
|
Vibrio cholerae (including El Tor)
|
2
|
T,V
|
Vibrio parahaemolyticus
|
2
|
|
Vibrio spp
|
2
|
|
Yersinia enterocolitica
|
2
|
|
Yersinia pestis
|
3
|
V
|
Yersinia pseudotuberculosis
|
2
|
|
Yersinia spp
|
2
|
|
VIRUSES
Biological Agent
|
Classification
|
Notes
|
Adenoviridae
|
2
|
|
Alphavirus
|
2* (contact NIV)
|
V
|
Arenaviridae:
|
|
|
Ippy
|
2
|
|
Lassa fever
|
4
|
|
Lymphocytic chloriomeningitis
|
3
|
|
Mobala
|
2
|
|
Mopeia
|
3
|
|
Astroviridae
|
2
|
|
Bunyaviridae:
|
|
|
Akabane
|
3
|
|
Bunyamwera
|
2
|
|
Germiston
|
3
|
|
Hantaviruses [contact NIV]
|
|
|
Nairoviruses:
|
|
|
Bhanja
|
3
|
|
Crimean / Congo haemorrhagic fever
|
4
|
|
Hazara
|
2
|
|
Phleboviruses:
|
|
|
Rift Valley fever
|
3
|
V
|
Other Bunyaviridae known to be pathogenic
|
2* (contact NIV)
|
|
Caliciviridae:
|
|
|
Hepatitis E
|
3
|
|
Norwalk
|
2
|
|
Other Caliciviridae
|
2
|
|
Coronaviridae
|
2
|
|
Filoviridae:
|
|
|
Ebola Reston (Siena)
|
4
|
|
Ebola Sudan
|
4
|
|
Ebola Zaire
|
4
|
|
Ebola Ivory Coast
|
4
|
|
Marburg
|
4
|
|
Flaviviridae:
|
|
|
Flaviviruses
|
|
|
Dengue viruses Type 1-4
|
3
|
|
Israel turkey meningitis
|
3
|
|
Spondweni
|
3
|
|
Wesselsbron
|
3
|
|
West Nile fever
|
3
|
|
Yellow fever
|
3
|
V
|
Hepatitis C group viruses:
|
|
|
Hepatitis C
|
3
|
|
Other Flaviviruses known to be pathogenic
|
2* [contact NIV]
|
|
Hepadnaviridae:
|
|
|
Hepatitis B
|
3
|
V
|
Hepatitis D(delta)
|
3
|
V
|
Herpesviridae:
|
|
|
Cytomegalovirus
|
2
|
|
Epstein-Barr virus
|
2
|
|
Herpes simplex types 1 and 2
|
2
|
|
Herpesvirus varicella-zoster
|
2
|
|
Herpesvirus simaie (B virus)
|
3
|
|
Human herpesvirus type 6 - HHV6
|
2
|
|
Human herpesvirus type 7 - HHV7
|
2
|
|
Orthomyxoviridae
|
|
|
Influenza types A, B and C2
|
2
|
V (for A,B)
|
Tickborne orthomyxoviridae:
|
|
|
Dhori and Thogoto
|
2
|
|
Papovaviridae:
|
|
|
BK and JC viruses
|
2
|
|
Human papillomaviruses
|
2
|
|
Paramyxoviridae
|
|
|
Measles
|
2
|
V
|
Mumps
|
2
|
V
|
Newcastle disease
|
2
|
|
Parainfluenza (Types 1 to 4)
|
2
|
|
Respiratory syncytial virus
|
2
|
|
Rinderpest
|
4
|
|
Canine distemper
|
|
|
Parvoviridae:
|
|
|
Human parvovirus (B19)
|
2
|
|
Picornaviridae
|
|
|
Acute haemorrhagic conjunctivitis
|
|
|
Virus (AHC)
|
2
|
|
Coxsackie viruses
|
2
|
|
Echoviruses
|
2
|
|
Polioviruses
|
2
|
V
|
Rhinoviruses
|
2
|
|
Hepatoviruses:
|
|
|
Hepatitis A
|
|
|
(Human enterovirus type 72)
|
2
|
V
|
Poxviridae:
|
|
|
Buffalopox
|
2
|
|
Cowpox
|
2
|
|
Milker’s nodes
|
2
|
|
Molluscum contagiosum virus
|
2
|
|
Monkeypox
|
3
|
V
|
Orf
|
2
|
|
Vaccinia
|
2
|
|
(including strains originally classified as rabbitpox virus)
|
|
|
Variola
(major and minor) (all strains, including “White virus”) |
4
|
V
|
Yatapox (Tana & Yaba)
|
2
|
|
Reoviridae:
|
|
|
Coltivirus
|
2
|
|
Human rotaviruses
|
2
|
|
Orbiviruses
(includes - African horsesickness serogroup L |
2
|
|
- Blue tongue serogroup L
|
|
|
Reoviruses
|
2
|
|
Retroviridae:
|
|
|
Human immunodeficiency viruses
|
3
|
|
Human T-cell lymphotropic viruses (HTLV) types 1 and 2
|
3
|
|
Simian immunodeficiency virus
|
3
|
|
Rhabdoviridae:
|
|
|
Lagos bat
|
3
|
|
Duvenhage
|
3
|
|
Makola
|
3
|
|
Rabies
|
3
|
V
|
Togaviridae:
|
|
|
Alphaviruses:
|
|
|
Chikungunya
|
3
|
|
Middelburg
|
2
|
|
Ndumu
|
3
|
|
O’nyong-nyong
|
2
|
|
Semliki forest
|
3
|
|
Sindbis
|
2
|
|
Rubiviruses:
|
|
|
Rubella
|
2
|
V
|
Toroviridae*
|
2
|
|
Unclassified viruses:
|
|
|
Blood-borne hepatitis viruses not yet identified
|
3
|
|
Equine morbillivirus
|
3
|
|
Unconventional agents:
|
|
|
-Associated with:
|
|
|
Creutzfeldt-Jakob disease
|
3
|
|
Gerstmann-Strussler-Scheinker syndrome
|
3
|
|
Kuru
|
3
|
|
- Including strains isolated from cats and exotic species e.g. elephants, cheetahs.
- Including strains originally classified as rabbitpox virus.
- All strains including “whitepox
virus”.
PARASITES
Biological Agent
|
Classification
|
Notes
|
Acathamoeba spp
|
2
|
|
Ancylostoma duodenale
|
2
|
|
Angiostrongylus cantonensis
|
2
|
|
Angiostriongylus costaricensis
|
2
|
|
Ascaris lumbriciodes
|
2
|
A
|
Ascaris suum
|
2
|
A
|
Babesia divergens
|
2
|
|
Babesia microti
|
2
|
|
Balantidium coli
|
2
|
|
Blastocystis homines
|
2
|
|
Brugia spp
|
2
|
|
Capillaria spp
|
2
|
|
Clonorchis- see Opisthorchis
|
|
|
Cryptosporidium spp
|
2
|
|
Cyclospora cayetanensis
|
2
|
|
Cyclospora spp
|
2
|
|
Dientamoeba fragilis
|
2
|
|
Dipetalonea - see Mansonella
|
2
|
|
Diphyllobothrium latum
|
2
|
|
Dracunculus medinensis
|
2
|
|
Echinococcus granulosus
|
3
|
|
Echinococcus multilocularis
|
3
|
|
Echinococcus vogeli
|
3
|
|
Entamoeba histolytica
|
2
|
|
Enterobius vermicularis
|
2
|
|
Enterocytozoon bieneusi
|
2
|
|
Fasciola gigantica
|
2
|
|
Fasciola hepatica
|
2
|
|
Fasciolopsis buski
|
2
|
|
Giardia lamblia (Giardia intestinalis)
|
2
|
|
Hymenolepis diminuta
|
2
|
|
Hymenolepis nana
|
2
|
|
Isopora belli
|
2
|
|
Leishmania brasiliensis
|
3
|
|
Leishmania donovani
|
3
|
|
Leishmania major
|
2
|
|
Leishmania tropica
|
2
|
|
Leishmania spp
|
2
|
|
Loa loa
|
2
|
|
Mansonella ozardi
|
2
|
|
Mansonella perstans
|
2
|
|
Mansonella streptocerca
|
2
|
|
Naegleria fowleri
|
3
|
|
Necator americanus
|
2
|
|
Onchocerca volvulus
|
2
|
|
Opisthorcis sinensis
(Chlonorchis sinensis) |
2
|
|
Opisthorchis viverrini
(Clonorchis viverrini) |
2
|
|
Opisthorchis felineus
|
2
|
|
Opisthorchis spp
|
2
|
|
Paragonimus spp
|
2
|
|
Plasmodium falciparum
|
3
|
|
Plasmodium spp (human & simian)
|
2
|
|
Sarcocystis suihominis
|
2
|
|
Schistosoma spp
|
2
|
|
Strongyloides spp
|
2
|
|
Taenia saginata
|
2
|
|
Taenia solium
|
3
|
|
Toxocara cants
|
2
|
|
Toxocara cati
|
2
|
|
Toxoplasma gondii
|
2
|
|
Trichinella native
|
2
|
|
Trichinella nelsoni
|
2
|
|
Trichinella pseudospiralis
|
2
|
|
Trichinella spiralis
|
2
|
|
Trichomonas vaginalis
|
2
|
|
Trichostrongylus orientalis
|
2
|
|
Trichostrongylus spp
|
2
|
|
Trichuris trichiura
|
2
|
|
Trypanosoma brucei brucei
|
2
|
|
Tryposoma brucei gambiense
|
2
|
|
Trypanosoma brucei rhodesiense
|
3
|
|
Trypanosoma cruzi
|
3
|
|
Trypanosoma rangeli
|
2
|
|
Wuchereria bancrofti
|
2
|
|
ANNEXURE C
PRECAUTIONS FOR
WORKPLACES
(Regulations 10(1)(b), 15(2) and 16(a), (b) and (c))
FIVE MAIN ROUTES OF TRANSMISSION:
- Contact
The
most important route of transmission in a workplace is by—
(a) direct contact with an infected or contaminated body surface or fluid; and
(b) indirect contact via contact with an object previously contaminated with
organisms from an infected person or animal.
- Droplet Transmission
Droplets are generated during coughing, sneezing, talking and during procedures such as suctioning.
Droplets may carry organisms that can infect a new host if they are deposited on conjunctivae, nasal mucosa or the mouth.
Droplets do not remain suspended in the air.
Droplets do not travel more than one metre.
- Airborne Transmission
Small particles (droplet nuclei) that remain suspended in air for long periods of time have a far greater potential for spreading disease than large droplets.
Few organisms are carried by this route, the most important being Mycobacterium tuberculosis and the viruses causing measles and chickenpox.
Prevention of spread requires an enclosed area with at least six air changes
per hour, or an open window that provides adequate ventilation.
- Common Vehicle Transmission
Transmission by items such as food, water, devices and equipment.
Normal hygienic practices and proper sterilisation or disinfection of
equipment should make this type of spread a rare event in certain
workplaces,
e.g. hospitals.
- Vector-Borne Transmission
Vectors such as mosquitoes, flies, fleas, etc. are hopefully not frequently encountered in workplaces as a cause of outbreaks.
In areas where there is a problem the appropriate measures, e.g. screens on windows and the use of insecticides must be instituted.
Two levels of precautions are recommended—
(a) Standard Precautions
These are applied at all times to all patients irrespective of their
diagnosis. All body fluids (except sweat) are regarded as potentially
infectious.
(b) Transmission-Based Precautions
These are applied when a specific infectious disease is diagnosed or
suspected.
The route by which the disease is transmitted will determine the category of
precautions that must be applied.
PRECAUTIONS
- Administrative Controls
- Education and Training
- Adherence to precautions
- Precautionary measures
- Standard Precautions
- Airborne Precautions
- Droplet Precautions
- Contact Precautions
- Formidable Epidemic Disease (e.g. viral haemorrhagic fevers) Precautions
- ADMINISTRATIVE CONTROLS
- EDUCATION AND TRAINING
A system must be developed to ensure that hospital patients, employees,
contractors and visitors are educated about—
* the use of precautions.
* their responsibility for adhering to the precautions.
- ADHERENCE TO PRECAUTIONS
Periodic evaluation of adherence to precautions must be carried out. The
findings are to be used to implement improvements.
- PRECAUTIONARY MEASURES
- STANDARD PRECAUTIONS
Standard precautions are used for the protection of all people exposed to
HBA.
1.1 HAND WASHING—
* Wash hands after touching blood, body fluid, secretions, excretions and
contaminated items, whether or not gloves are worn.
* Wash hands (when working with patients)—
➢ immediately after gloves are removed.
➢ between patient contact.
➢ where indicated to prevent cross-contamination of different body sites.
* Use plain (non-antimicrobial) soap for routine hand washing.
* Use an antimicrobial agent or an alcohol hand disinfectant for specific
circumstances (e.g. control of outbreaks or hyperendemic
infections) as defined
by the infection control program. (See contact precautions.)
1.2 GLOVES—
- Wear gloves (clean, intact non-sterile gloves are adequate) when touching blood, body fluid, secretions, excretions and contaminated items.
* Put on clean intact gloves just before touching mucous membranes and non-intact skin.
* Change and dispose of gloves between tasks and procedures—
➢ on the same person.
➢ after contact with material that may contain high concentration of micro-organisms.
* Remove gloves promptly after use—
➢ before touching non-contaminated items and environmental surfaces.
➢ before attending to another person.
* Wash hands immediately to avoid transfer of micro-organisms to other
persons and environments.
1.3 MASK, EYE PROTECTION, FACE SHIELD
* Wear a mask and eye protection or a face shield—
➢ to protect mucous membranes of the eyes, nose and mouth.
➢ during procedures and activities that are likely to generate splashes or sprays of blood or body fluid, secretions and excretions.
1.4 PROTECTIVE CLOTHING
* Wear appropriate protective clothing to protect skin and to prevent soiling of clothing during procedures and activities that are likely to generate splashes or sprays of blood, body fluid, secretions and excretions.
* Select protective clothing that is appropriate for the activity and amount of fluid likely to be encountered.
* Remove soiled protective clothing as promptly as possible and consider it contaminated.
* Wash hands immediately after removal of protective clothing to avoid
transfer of micro-organisms to other people or environments.
1.5 PATIENT-CARE EQUIPMENT
* Handle patient-care equipment soiled with blood, body fluids, secretions
and excretions in a manner that prevents—
➢ skin and mucous membrane exposures.
➢ contamination of clothing.
➢ transfer of micro-organisms to other environments.
* Ensure that reusable equipment is not used for the care of another patient
until—
➢ it has been cleaned.
➢ it has been reprocessed appropriately.
* Ensure that—
➢ sufficient disposable syringes and needles are at all times available for use.
➢ provision is made for their safe disposal.
1.6 ENVIRONMENTAL CONTROL
* Ensure that adequate procedures are in place for routine care, cleaning and disinfection of environmental surfaces, and other frequently used or potentially contaminated surfaces.
* Disinfection of environmental surfaces is not routinely required. Simple
cleaning is adequate unless there has been significant
soiling by potentially
infectious body fluids.
1.7 LINEN
* Process, handle and transport used linen contaminated with blood, body
fluid, secretion and excretions in colour coded, impervious
containers and all,
possible measures should be observed to prevent—
➢ skin and mucous membrane exposure.
➢ contamination of clothing.
➢ transfer of micro-organisms to other persons and environments.
1.8 OCCUPATIONAL HEALTH
1.8.1 Injuries
* Take care to prevent injuries when
➢ using needles, scalpels and other sharp instruments or devices.
➢ handling sharp instruments after a procedure.
➢ cleaning instruments.
➢ disposing of used needles.
Never
* Re-cap needles or manipulate them using both hands, if it is absolutely necessary to resheath a needle. A variety of mechanical devices that are commercially available must be used.
* Use any other technique that involves directing the point of a needle
toward any part of the body.
Do not
* Remove used needles from disposable syringes by hand.
* Bend or break or otherwise manipulate needles by hand.
Do
* Place used disposable syringes and needles, scalpel blades and other sharp objects in appropriate puncture-proof containers that are as close as possible to the area in which the procedure is carried out.
* Transport them safely to the disposal area.
1.8.2 Resuscitation
Use mouthpieces, resuscitation bags or other ventilation devices as an
alternative method to mouth-to-mouth resuscitation in areas
where the need for
resuscitation is predictable.
1.9 PATIENT PLACEMENT
* Place in an isolation area (single or private room) patients
who—
➢ contaminate the environment.
➢ do not or cannot be expected to assist in maintaining appropriate personal hygiene or environmental control.
* If an isolation area is not available, consult infection control
professionals regarding patient placement or other
alternatives.
2. AIRBORNE PRECAUTIONS
In addition to Standard Precautions, use Airborne Precautions
for—
* patients known or suspected of being infected with micro-organisms
transmitted by airborne droplet nuclei, i.e. small particle residue
of
evaporated droplets containing micro-organisms that—
➢ remain suspended in the air;
➢ can be widely dispersed by air currents within a room or over a long distance.
2.1 PATIENT PLACEMENT
Ideally place patients in a private room that has—
* monitored negative air pressure in relation to the surrounding areas.
* 6-12 air changes per hour.
* Appropriate discharge of air outdoors or monitored high-efficiency
filtration of room air before the air is circulated to other
areas of the
hospital.
Where this is not possible—
* Use—
➢ a room with a simple extraction fan providing at least six air changes per hour.
➢ a room with an open window, and adequate ventilation.
* When an isolation area is not available, place the patient in a room with another patient who has active infection with the same micro-organism, and no other infection, unless otherwise recommended.
* When a private room is not available and cohorting is not desirable, consultation with infection control professionals is advised before patient placement.
* Keep the patient in the room and keep the door closed.
2.2 RESPIRATORY PROTECTION
Tuberculosis—
* Respiratory protection may be worn when entering the room of a patient known or suspected to have infectious pulmonary tuberculosis.
* Measles (rubeola) and chickenpox (varicella).
* Susceptible persons should not enter the room of patients known or suspected of having measles or varicella if other immune caregivers are available.
* If susceptible persons must enter the room they must wear respiratory protection.
* Persons immune to measles or varicella need not wear respiratory
protection.
2.3 PATIENT TRANSPORT
Movement and transport of the patient should be kept to a minimum.
* If transport or movement is necessary, the patient must wear a surgical
mask to minimise dispersal of droplet nuclei.
2.4 ADDITIONAL PRECAUTIONS FOR PREVENTING TRANSMISSION OF
TUBERCULOSIS
* Respirators—
➢ must be worn by all who enter the room.
➢ must be able to filter particles 1 micron or less in size with a filter efficiency of 95%.
* Effective treatment of the patient
* Isolation—
➢ there is significant clinical improvement in the patient’s condition.
➢ ideally, two negative acids fast bacilli smears must be obtained.
➢ ideally a smear positive patient will require isolation for a minimum of two weeks.
3. DROPLET PRECAUTIONS
In addition to Standard Precautions, use Droplet Precautions for patients
known or suspected to be infected with micro-organisms transmitted
by droplets
(large particle droplets that can be generated during coughing, sneezing,
talking or respiratory therapy).
3.1 PATIENT PLACEMENT
Place the patient in an isolation area, e.g. private or single
room—
* When a private room is not available and cohorting is not achievable, maintain spatial separation of at least one metre between the infected patient and other patients and visitors.
* Additional ventilation measures are not necessary and the door may remain
open.
3.2 MASKS
Wear a mask when working within one metre of the patient. However,
logistically some hospitals may want to implement the wearing of
a mask to enter
the room.
3.3 PATIENT TRANSPORT
Movement and transport of the patient from the room should be kept to a minimum, if transport or movement is necessary, minimise dispersal of droplets by masking the patient.
- CONTACT PRECAUTIONS
In addition to Standard Precautions use Contact Precautions
for—
specified patients known or suspected to be infected or colonised with
epidemiologically important micro-organisms that can be transmitted
by direct
contact with the patient (hand to skin contact occurs when performing patient
care activities that required touching the
patient’s dry skin) - or
indirect contact (touching) environmental surfaces or patient care items in the
patient’s environment.
4.1 PATIENT PLACEMENT
Place the patient in an isolation area, e.g. private or single
room—
* When a private room is not available, place the patient in a room with patients who have active disease with the same microorganism but no other infection (cohorting).
* When neither a private room nor cohorting is achievable, consider the epidemiology of the microorganism and the patient population when determining patient placement.
Consultation with infection control professionals is advisable before patient
placement.
4.2 GLOVES AND HAND WASHING
In addition to wearing gloves and washing hands as outlined in Standard
Precautions—
* Wear clean gloves when entering the room.
* Change gloves after having contact with infective material.
* Remove gloves before leaving the patient’s environment.
* Wash hands immediately after glove removal with an antimicrobial or an alcohol hand rub.
* Ensure that hands do not touch potentially contaminated environmental
surfaces or items in the patient’s room to avoid transfer
of
micro-organisms to other patients or the environment.
4.3 PROTECTIVE CLOTHING
In addition to wearing a gown or plastic apron as outlined in Standard
Precautions—
* Wear a clean, non-sterile gown and / or plastic apron as
appropriate—
➢ when entering a room where soiling of clothing is anticipated;
➢ following substantial contact with the patient;
➢ following contact with environmental surfaces or items in the patient’s room;
➢ if the patient is incontinent or has diarrhoea, an ileostomy or a colostomy;
➢ where wound drainage is not contained by a dressing;
* Remove the gown or plastic apron before leaving the patient’s environment.
* After gown or plastic apron removal, ensure that clothing does not make
contact with potentially contaminated environmental surfaces
to avoid transfer
of microorganisms to other patients or environments.
4.4 PATIENT TRANSPORT
* Movement and transport of the patient from the room should be minimised.
* Ensure that precautions are maintained to minimise the risk of transmission of micro-organisms to other patients and contamination of environmental surfaces or equipment.
4.5 PATIENT-CARE EQUIPMENT
Where possible dedicate the use of non-critical patient-care equipment to a single patient (or cohort of patients infected or colonised with the pathogen requiring precautions).
Avoid sharing equipment between patients
- If the use of common equipment or items is unavoidable, then these must be
cleaned and disinfected before use for another patient.
4.6 ADDITIONAL PRECAUTIONS FOR PREVENTING THE SPREAD OF MULTI DRUG-RESISTANT
MICRO-ORGANISMS
* Limit antibiotic use and prevent misuse.
* Educate staff.
* Detect multi-drug-resistant micro-organisms early by laboratory and infection control surveillance.
* Consult an Infection Control Practitioner regarding further
management.
- FORMIDABLE EPIDEMIC DISEASE (FED) ISOLATION
* Standard and contact precautions plus additional items such as respirators, visors, water repellent gowns and boots, caps, double gloves are required.
* Standard precautions are adequate during the non-haemorrhagic phase in
cases of haemorrhagic fevers, such as Ebola and Congo-Crimean
haemorrhagic
fever.
5.1 ISOLATION AREA
* This may be a dedicated viral haemorrhagic fever (VHF) unit or a dedicated sideward or private room, preferably with an anteroom.
* The door must be kept closed, and strict access control must be
implemented.
5.2. GOWNS
* Impervious disposable gowns must be worn over a theatre scrub suit.
5.3 GLOVES
* Two pairs are worn, the one pair on top of the other.
* Sterile latex gloves are used because of the thicker quality and longer
non-roll cuff.
5.4 BOOTS
* Impervious boots or overshoes are worn in the isolation room.
They must be—
➢ high enough to cover the area of skin below the trouser legs.
➢ strong enough to withstand wear and tear.
5.5 THEATRE CAPS / GOGGLES OR VISORS
* Worn inside the isolation room.
* Theatre caps.
A theatre cap worn with a visor providing full protection of the head and
neck is preferred.
5.6 MASKS AND RESPIRATORS
* Masks good quality, high-filtration respirators are necessary.
5.7 Formidable Epidemic Disease Pack (FED Pack)
A FED pack contains all the isolation gear necessary, must be safely stored in an area not accessible to unauthorised persons. The FED pack must be immediately replenished after every usage.
This pack is available immediately, is portable and is used until the patient
is diagnosed or transferred to an isolation unit or
an infectious diseases
hospital. The pack is kept in a box or in a trolley. The box (or trolley) is
distinctive and kept in an easily
accessible place. The pack contents are
replenished as required by the infection control staff.
Instruction posters provide instructions for untrained personnel until
infection control professionals arrive to provide guidance
and instruction in
VHF procedures.
Contents—
* Sterile latex gloves of varying sizes;
* Disposable impermeable gowns;
* Goggles or visors;
* Masks;
* Shoe covers (half-leggings).
Theatre caps.
* Blood tubes, labels, bio-hazard plastic specimen bags, a rigid, walled container for transportation of specimens and bio-hazard stickers.
* Masking tape used for—
➢ sealing boxes of refuse.
➢ fixing instruction posters to the wall.
➢ securing tops of plastic shoe covers.
* Plastic refuse bags for contaminated refuse.
* Autoclavable bags for non-disposable items.
* Clear plastic bags.
* Sodium-hypochlorite sachets of powder (NaOCI) and liquid 1% hypochlorite.
* Plastic-covered instruction posters containing detailed instructions on how
to—
➢ put on isolation gear;
➢ undress safely;
➢ collect and handle specimens safely;
➢ mix disinfectants;
➢ disinfect and handle contaminated equipment;
➢ dispose of linen and refuse;
➢ deal with a blood spill.
5.8 The infection control professionals must ensure that staff follows
correct procedures and that equipment is available for disposal
of
refuse—
* All refuse bags are colour coded, double bagged and are placed into cardboard boxes.
* Refuse bags are sealed and labelled with bio-hazard stickers and tape.
* Containers are escorted to the incinerator.
* Their immediate incineration is ensured.
5.9 Transporting VHF specimens—
These specimens require a special container and packaging—
➢ The specimen is placed in a bio-hazard bag.
➢ The patient’s label is placed in the outer pouch.
➢ The specimen is then wrapped in absorbent material and placed in an unbreakable screw-top container.
➢ The container is labelled with a bio-hazard sticker and the destination (name of the receiving laboratory).
➢ It is preferably delivered by hand.
➢ If the specimen has to be posted or sent by courier a second unbreakable container is used and labelled accordingly.
5.10 Management of soiled linen, refuse and equipment
Bedding
* All bedding used is either disposable or condemned linen that is subsequently incinerated.
* Mattresses must be covered with durable plastic covers—
➢ The covers are disposable.
➢ If the mattress becomes soiled with blood or body substance it must be destroyed.
Linen and Refuse
* All linen (disposable and condemned) is placed into plastic refuse
bags—
➢ The person inside the cubicle or room takes the sealed bag and places it in a second bag held by another person outside the room.
➢ This bag is then sealed and sent for incineration.
Terminal disinfection of equipment
* All equipment is washed down well with a hypochlorite-detergent.
* It is then dried, using a paper towel.
If the equipment is not autoclavable, it must be wrapped in clear plastic
bags, then—
➢ double bagged into a clean bag held by a second person outside the cubicle.
➢ clearly labelled with the contents and a biohazard sticker attached.
➢ sent to Central Sterilising Service Department (CSSD) for ethylene oxide gas sterilisation.
* Autoclavable items must be placed in Asepto type bags—
➢ labelled as above;
➢ sealed in clean plastic bags for transport to CSSD;
➢ autoclavable plastic bags may be used if available.
Furniture or environment
* All furniture, walls and floors are washed down well with
hypochlorite-detergent.
TABLE I
Infection / Condition
|
Precautions Type*
|
Duration
|
Abscess
|
|
|
Draining, majora
|
C
|
DI
|
Draining. minor or limitedb
|
S
|
|
AIDSc
|
S
|
|
Actinomycosis
|
S
|
|
Adenovirus infection, in infants and young children
|
D, C
|
DI
|
Amebiasis
|
S
|
|
Anthrax
|
|
|
Cutaneous
|
S
|
|
Pulmonary
|
S
|
|
Antibiotic-associated colitis (seeC difficile)
|
|
|
Arthropodborne viral encephalitides (eastern. western, Venezuelan equine
encephalomyelitis: St Louis, California encephalitis)
|
Sd
|
|
Arthropodborne viral fevers (dengue, yellow fever, Colorado tick fever)
|
Sd
|
|
Ascariasis
|
S
|
|
Aspergillosis
|
S
|
|
Babesiosis
|
S
|
|
Blastomycosis, North American, cutaneous or pulmonary
|
S
|
|
Botulism
|
S
|
|
aNo dressing or dressing does not adequately contain
damage
|
|
|
bDressing covers and adequately contains drainage
|
|
|
Bronchiolitis (see respiratory infections in infants and young
children)
|
|
|
Brucellosis (undulant, Malta, Mediterranean fever)
|
S
|
|
Campylobacter gastroenteritis (see gastroenteritis)
|
|
|
Candidiasis. all forms including mucocutaneous
|
S
|
|
Cat-scratch fever (benign inoculation lymphoreticulosis)
|
S
|
|
Cellulitis, uncontrolled drainage
|
C
|
DI
|
Chancroid (soft chancre)
|
S
|
|
Chickenpox (varicella) (see F for varicella exposure)
|
A, C
|
Fe
|
Chlamydia trachomatis
|
|
|
Conjuctivitis
|
S
|
|
Genital
|
S
|
|
Respiratory
|
S
|
|
Cholera (see gastroenteritis)
|
|
|
Closed-cavity infection
|
|
|
Draining, limited or minor
|
S
|
|
Not draining
|
S
|
|
Clostridium spp
|
|
|
C. botulium
|
S
|
|
C.difficile
|
C
|
DI
|
C. perfringens
|
|
|
Food poisoning
|
S
|
|
Gas gangrene
|
S
|
|
Coccidiodomycosis (valley fever)
|
|
|
Draining lesions
|
S
|
|
Pneumonia
|
S
|
|
Colorado tick fever
|
S
|
|
Congenital rubella
|
C
|
F
|
Conjunctivitis
|
|
|
Acute bacterial
|
S
|
|
Chlamydia
|
S
|
|
Conococcal
|
S
|
|
Acute viral (acute hermorhagic)
|
C
|
DI
|
CoxsackIe virus (see enteroviral infection)
|
|
|
Creutzfeldt-Jakob disease
|
Sd
|
|
Croup (see respiratory in Infants and young children)
|
|
|
Cryptococcosis
|
S
|
|
Cryptosporidiosis (see gastroenteritis)
|
|
|
Cysticercosis
|
S
|
|
Cytomegalovirus infection neonatal or immunosuppressed
|
S
|
|
Decubitus ulcer, infected
|
|
|
Majora
|
C
|
DI
|
Minor or limitedb
|
S
|
|
Dengue
|
Sd
|
|
Diarrhea acute-infective etiology suspected (sse
gastroenteritis)
|
|
|
Diptheria
|
|
|
Cutaneous
|
C
|
CNn
|
Pharyngeal
|
D
|
CNn
|
Ebola Viral hemorrhagic fever
|
C
|
DI
|
Echnococcosis (hydatidosis)
|
S
|
|
Echovirus (see enteroviral enfection)
|
|
|
Encephalitis (see enteroviral infection)
|
|
|
Encephalitis or encephalomyelitis (see specific etiologic
agents)
|
|
|
Endometritis
|
S
|
|
Enterobiasis (pinworm disease, oxyuriasis)
|
S
|
|
Enterococcus species (see multidrug-resistant organisms if
epdidemiologically significantorvancomycin resistant)
|
|
|
Enterocolitis. C. difficiie
|
C
|
DI
|
Enteroviral infctions
|
|
|
Adults
|
S
|
|
Infants and young children
|
C
|
DI
|
Epiglottitis caused by H. influenzea
|
D
|
U24 hrs
|
Epstein-Barr virus infection, including infectious mononucleosis
|
S
|
|
Erythema infectiosum (also see Parvovirus B19)
|
S
|
|
Escherichia coli gastroenteritis (see gastroenteritis)
|
|
|
Food poisoning
|
|
|
Botulism
|
S
|
|
Clostridium perfringens or welchii
|
S
|
|
Staphylococcal
|
S
|
|
Furunculosis-staphylococcal
|
|
|
Infants and young children
|
C
|
DI
|
ngrene (gas gangrene)
|
S
|
|
Gastroenteritis
|
|
|
Campylobacter sp
|
Si
|
|
Cholera
|
Si
|
|
C.difficile
|
C
|
DI
|
Cryptosporidium species
|
Si
|
|
E. coli
|
|
|
Enterohemorrhagic 0157.H7
|
Si
|
|
Diapered or incontinent
|
C
|
DI
|
Other species
|
Si
|
|
Giardia lamplia
|
Si
|
|
Rotavirus
|
Si
|
|
Diapered or incontinent
|
C
|
DI
|
Salmonella species (including S. typhi)
|
Si
|
|
Shigella species
|
Si
|
|
Diapered or incontinent
|
C
|
DI
|
Vibrio parahamolyticus
|
Si
|
|
Viral (if not covered elsewhere)
|
Si
|
|
Yersinia enterocolitica
|
Si
|
|
German measles (rubella)
|
D
|
Fv
|
Giardiasis (see gastroenteritis)
|
|
|
Gonococcal ophthalmia neonatorum (gonorrheal ophtalmia acute
conjunctivitis of newborn) |
S
|
|
Gonorrhea
|
S
|
|
Granuloma inguinale (donovanosis, granuloma venereum)
|
S
|
|
Guillain-Barre syndrome
|
S
|
|
Hand, foot and mouth disease (see enterviral infection)
|
|
|
Hantavirus pulmonary syndrome
|
S
|
|
Helicobacter pylori
|
S
|
|
Hemorrhagic fevers (for example Lassa and Ebola)
|
Ci
|
DIi
|
Hepatitis, viral
|
|
|
Type A
|
S
|
|
Diapered or incontinent patients
|
C
|
Fk
|
Type B-HBsAg positive
|
S
|
|
Type C and other unspecified, non-A, non-B
|
S
|
|
Type E
|
S
|
|
Herpangina (see enteroviral infection)
|
|
|
Herpes simplex (Herpesvirus hominis)
|
|
|
Encephalitis
|
S
|
|
Neonatal (see F for neonatal exposure)
|
C
|
DI
|
Mucocutaneous disseminated or primary severe
|
C
|
DI
|
Mucocutaneous, recurrent (skin, oral, genital)
|
S
|
|
Herpes zoster (varicella zoster)
|
|
|
Localised in immunocompromised patient or disseminated
|
A, C
|
DIm
|
Localised in normal patient
|
Sm
|
|
Histoplasmosis
|
S
|
|
HIV (see human immunodeficiency virus)
|
S
|
|
Hookworm disease (ancyclostomiasis, uncinariasis)
|
S
|
|
Human immunodeficiency virus (HIV) Infection
|
S
|
|
Impetigo
|
C
|
U24 hrs
|
Infectious mononucleosis
|
S
|
|
Influenza
|
Dn
|
DI
|
Kawasaki syndrome
|
S
|
|
Lassa fever
|
C
|
DI
|
Legionnaires disease
|
S
|
|
Leprosy
|
S
|
|
Leptospirosis
|
S
|
|
Lice (pediculosis)
|
C
|
U24 hrs
|
Listeriosis
|
S
|
|
Lyme disease
|
S
|
|
Lymphocytic choromeninggitis
|
S
|
|
Lymphogranoloma venereum
|
S
|
|
Malaria
|
S
|
|
Marburg virus disease
|
A
|
DI
|
Measles (rubeola) all presentations
|
A
|
DI
|
Meliodiosis all forms
|
S
|
|
Meningitis
|
|
|
Aseptic (non bacterial or viral meningitis) (also see enteroviral
infections) |
S
|
|
Bacterial, gram-negative enteric in neonates
|
S
|
|
Fungal
|
|
|
H. influenza, known or suspected
|
D
|
U24 hrs
|
Listeria monocytogenes
|
S
|
|
Neisseria meningitidis (meningococcal) known or
suspected
|
D
|
U24 hrs
|
Pneumococcal
|
S
|
|
Tuberculosis
|
S
|
|
Other diagnosed bacterial
|
S
|
|
Meningococcal pneumonia
|
D
|
U24 hrs
|
Meningococcal (meningococcal sepsis)
|
D
|
U24 hrs
|
Molluscum contagiosum
|
S
|
|
Mucormycosis
|
S
|
|
Multidrug-resistant organisms, infection or colonisation
|
|
|
Gastrointestinal
|
C
|
CN
|
Respiratory
|
C
|
CN
|
Pneumococcal
|
S
|
|
Skin, Wound or burn
|
C
|
CN
|
Mumps (infections parotitis)
|
D
|
F2
|
Mycobacteria non tuberculosis (atypical)
|
|
|
PuImonary
|
S
|
|
Wound
|
S
|
|
Mycoplasma pneumonia
|
D
|
DI
|
Necrotizing enterocolitis
|
S
|
|
Nocardiosis draining lesions or ther presentations
|
S
|
|
Norwalk agent gastroenteritis (see viral gastroenteritis)
|
|
|
Orf
|
S
|
|
Parainfluenza virus infection, respiratory in Infants and young children
|
C
|
DI
|
Parvovirus B19
|
D
|
F
|
Pediculosis (lice)
|
C
|
U24 hrs
|
Pertussis (whooping cough)
|
D
|
Fs
|
Pinworm infection
|
S
|
|
Plague
|
|
|
Bubonic
|
S
|
|
Pneumonic
|
D
|
U24 hrs
|
Pleurodynia (see enterovival infection)
|
|
|
Pneumonia
|
|
|
Adenovirus
|
D, C
|
DI
|
Bacterial not listed elsewhere (including gram-negative bacterial)
|
S
|
|
Burkholderia cepacia in patience with CF including respiratory
tract
colonisation |
S
|
|
Clamydia
|
S
|
|
Fungal
|
|
|
H. influenzae
|
|
|
Adults
|
S
|
|
Infants and children (any age)
|
D
|
U24 hrs
|
Legionella
|
S
|
|
Meningococcal
|
D
|
U24 hrs
|
Multidrug – resistant bacterial (see multidrug-
resistant organisms)
|
|
|
Mycoplasma (primary atypical pneumonia)
|
D
|
DI
|
Pneumococcal
|
|
|
Multidrug- resistant (see multidrug -resistant
organisms)
|
|
|
Pneumocystis carinii
|
S
|
|
Pseudomonas cepacia (see Burkholderia cepacia)
|
S
|
|
Staphylococcus aureus
|
S
|
|
Streptococcus, Group A
|
|
|
Adults
|
S
|
|
Infants and children
|
D
|
U24 hrs
|
Viral
|
|
|
Adults
|
S
|
|
Infants and young children (see respiratory infectious
disease,
acute) |
|
|
Poliomyelitis
|
S
|
|
Psittacosis (ornithosis)
|
S
|
|
Q fever
|
S
|
|
Rabies
|
S
|
|
Rat-bite fever (Streptopacillus moniliformis disease. Spirillum minus
disease)
|
S
|
|
Relapsing fever
|
S
|
|
Resistant bacterial infection or colonisation (see multidrug resistant
organisms)
|
|
|
Respiratory infectious disease acute (if not covered
elsewhere)
|
|
|
Adults
|
S
|
|
Infants and young children
|
C
|
DI
|
Respiratory syncytial virus infection in infants and young children and
immunocompromisedadults
|
C
|
DI
|
APPENDIX A.
|
|
|
Reye’s syndrome
|
S
|
|
Rheumatic fever
|
S
|
|
Rickettsiai fever, tickborne (Rocky Mountain spotted fever, tickborne
typhus fever)
|
S
|
|
Rickettsialpox (vesicular rikettsiosis)
|
S
|
|
Ringworm (dermatophytosis, dermatomycosis, tinea)
|
S
|
|
Ritter’s disease (staphylococcal scalded skin syndrome)
|
S
|
|
Rocky Mountain spotted fever
|
S
|
|
Roseola infantum (exanthum subitum)
|
S
|
|
Rotavirus infection (see gastroenteritis)
|
|
|
Rubella (German measles) (also see congenital rubella)
|
D
|
Fv
|
Salmonellosis (see gastroenteritis)
|
|
|
Scabies
|
C
|
U24 hrs
|
Scalded skin syndrome, staphylococcal (Ritter’s disease)
|
S
|
|
Schistosomiasis (bilharziasis)
|
|
|
Shigellosis (see gastroenteritis)
|
|
|
Sporotrichosis
|
S
|
|
Spirillium minus disease (rat-bite fever)
|
S
|
|
Staphylococcal disease (S. aureus)
|
|
|
Skin wound or burn
|
|
|
Major
|
C
|
DI
|
Minor or limited
|
S
|
|
Enserocolitis
|
S
|
|
Multidrug resistant (see multidrug-resistant organisms)
|
|
|
Pneumonia
|
S
|
|
Scalded skin syndrome
|
S
|
|
Toxic shock syndrome
|
S
|
|
Streptobacillus moniliformis disease (rat-bite fever)
|
S
|
|
Streptococcal disease (groupA Streptococcus)
|
|
|
Skin wound or burn
|
|
|
Major
|
C
|
U24 hrs
|
Minor or limited
|
S
|
|
Endometritis (puerperalsepsis)
|
S
|
|
Pharyngitis in infant and young children
|
D
|
U24 hrs
|
Pneumonia in infant and young children
|
D
|
U24 hrs
|
Scarlet fever in infant and young children
|
D
|
U24 hrs
|
Streptococcal disease (group B Streptococcus) neonatal
|
S
|
|
Streptococcal disease (not group A or B) unless covered elsewhere
|
S
|
|
Multidrug-resistant bacterial (see multidrug-resistant
organisms)
|
|
|
Strongyloidiasis
|
S
|
|
Syphilis
|
|
|
Skin and mucous membrane including congenital primary secondary
|
S
|
|
Latent (tertiary) and seropositivity without lesions
|
S
|
|
Tapeworm disease
|
|
|
Hymenolepis nana
|
S
|
|
Taenia soluim (pork)
|
S
|
|
Other
|
S
|
|
Tetanus
|
S
|
|
Tinea (fungus infection dermatophytosis dermatomycosis ringworm)
|
S
|
|
Toxoplasmosis
|
S
|
|
Toxic shock syndrome (staphylococcal disease)
|
S
|
|
Trachoma acute
|
S
|
|
Trench mouth (Vincent angina)
|
S
|
|
Trichinosis
|
S
|
|
Trichomoniasis
|
S
|
|
Trichuriasis (whipworm disease)
|
S
|
|
Tuberculosis
|
|
|
Extrapulmonary draining lesion (including scrofula)
|
S
|
|
Extrapulmonary mengitis
|
S
|
|
Pulmonary confirmed or suspected or laryngeal disease
|
A
|
Fw
|
Skin-test positive with no evidence of current pulmonary
disease
|
S
|
|
Tularemia
|
|
|
Draining lesion
|
S
|
|
Pulmonary
|
S
|
|
Typhoid (Salmonella typhi) fever (see gastroenteritis)
|
|
|
Typhus endemic and epidemic
|
S
|
|
Urinary tract infection (including pyelonephritis) with or without urinary
catheter
|
S
|
|
Varicella (chickenpox)
|
A.C
|
Fe
|
Vibrio parahaernolytlcus (see gastroenteritis)
|
|
|
Vincent’s angina (trench mouth)
|
S
|
|
Viral deceases
|
|
|
Respiratory (if not covered elsewhere)
|
|
|
Adults
|
S
|
|
Infants and young children (see respiratory infectious disease
acute)
|
|
|
Whooping cough. (pertussis)
|
D
|
Fg
|
Wound infections
|
|
|
Major
|
C
|
DI
|
Minor or Limited
|
S
|
|
Yersinia entercolitica gastroenteritis (see gastroenteritis)
|
|
|
Zoster (varicella-zoster)
|
|
|
Localised in immune compromised patient, disseminated
|
A.C
|
DIm
|
Localised in normal patient
|
Sm
|
|
Zygomycosis (phycomycosis mucormycosis)
|
S
|
|
Abbreviations used
Type of
precautions—
Standard precautions (S) are applied at all times
in addition to either—
- Airborne
- Contact
- Droplet
VHF Viral haemorrhagic fever
Duration of
precautions—
- duration of hospitalisation
- duration of illness (with wound lesions, Dl means until they stop draining)
- until time specified in hours (hrs) after initiation of effective therapy.
- footnote number under type
Meaning of superscript number (i.e. FE
Standard precaution is applied at all times)
aNo dressing, or
dressing does not contain drainage adequately.
bDressing
covers and contains drainage adequately.
cAlso see syndromes
or conditions listed in Table 2.
dInstall screens in windows
and doors in endemic areas.
eMaintain precautions until
all lesions are crusted. The average incubation period for varicella is 10 to 16
days, with a range of
10 to 21 days. After exposure, use varicella-zoster immune
globulin (VZIG) when appropriate and discharge susceptible patients if
possible.
Place exposed susceptible patients on Airborne Precautions beginning 10 days
after exposure and continuing until 21 days
after last exposure (up to 28 days
if VZIG has been given). Susceptible persons should not enter the room of the
isolated patient
on precautions if other immune caregivers are
available.
fIsolate all infants on precautions during any
admission until one year of age, unless nasopharyngeal and urine cultures are
negative
for virus after age three months of age.
gAdditional
special precautions are necessary for handling and decontamination of blood,
body fluids and tissues, and contaminated
items from patients with confirmed or
suspected disease.
hUntil two cultures are taken at least 24
hours apart are negative.
iConsult the National Institute of
Virology for guidelines issued by provincial health departments. Use Contact
Precautions for diapered
or incontinent children less than six years of age for
duration of illness. Maintain precautions in infants and children under three
years of age for duration of hospitalisation; in children three to 14 years of
age, until two weeks after onset of symptoms; and
others, until one week after
onset of symptoms. For infants delivered vaginally or by Caesarean section and
if mother has active
infection and membranes have been ruptured for more than
four to six hours.
mPersons susceptible to varicella are also
at risk for developing varicella when exposed to patients with zoster lesions;
therefore,
susceptibles should not enter the room if other immune caregivers are
available.
nMany hospitals encounter logistic difficulties and
suspected or diagnosed limitations when admitting multiple patients with
suspected
influenza during community outbreaks. If sufficient private rooms are
unavailable, consider cohorting patients or, at the very least,
avoid room
sharing with high-risk patients.
oPatients should be examined
for evidence of current (active) pulmonary tuberculosis. If evidence exists,
additional precautions are
necessary (see tuberculosis
3).
pResistant bacteria judged by the infection control
program, based on current state, regional or national recommendations, to be of
special clinical and epidemiologic significance.
For nine days after
onset of swelling.
Maintain precautions for duration of hospitalisation
when chronic disease occurs in an immunodeficient patient. For patients with
a
transient plastic crisis or red cell crisis, maintain precautions for seven
days.
Maintain precautions for five days after patient is placed on
effective therapy.
Avoid cohorting or placement in the same room with a
cystic fibrosis (CF) patient who is not infected or colonised with B. cepacia.
Persons with CF who visit or provide care and are not infected or colonised with
B. cepacia may elect to wear a mask when within
one metre of a colonised or
infected patient.
Avoid placement in the same room with an
immunocompromised patient.
Until seven days after onset of
rash.
Discontinue precautions only when TB patient is improving
clinically and has three consecutive negative sputum smears collected on
different days or TB is ruled out.
Maintain all precautions until the
patient stops bleeding.
TABLE II
CLINICAL SYNDROMES OR CONDITIONS WARRANTING ADDITIONAL EMPIRIC
PRECAUTIONS TO PREVENT TRANSMISSION OR EPIDEMIOLOGICALLY IMPORTANT
PATHOGENS
PENDING CONFIRMATION OF DIAGNOSIS*
Clinical Syndrome or Condition**
|
Potential Pathogens
|
Empiric Precautions
|
Diarrhoea
|
|
|
Acute diarrhoea-like infections:
Contact cause in an incontinent or diapered patient. |
Enteric pathogens***
|
Contact
|
Diarrhoea in an adult with a history of recent antibiotic use Rash or
exanthems, generally, etiology unknown
|
Clostridium
|
Droplet
|
Petechial or ecchymotic with fever
|
Neisseria meningitides
|
Droplet
|
Vesicular
|
Varicella
|
Airborne and contact
|
Maculopapular with coryza and fever
|
Measles
|
Airborne
|
Respiratory infections
|
|
|
Cough / fever / upper lobe pulmonary infiltrate in an HIV-negative patient
or a patient at low risk for HIV infection
|
Mycobacterium tuberculosis
|
Airborne
|
Cough / fever / pulmonary infiltrate in any lung location in an
HIV-infected patient or a patient at high risk of HIV infection
|
Mycobacterium tuberculosis
|
Airborne
|
Paroxysmal or severe persistent cough during periods of pertussis
activity
|
Bordella pertussis
|
Droplet
|
Particularly bronchiolitis and croup in infants and young children
|
Respiratory syncytial virus or parainfluenza virus
|
Contact
|
Risk of multidrug-resistant micro-organisms
|
|
|
History of infection or colonisation with multidrug-resistant
organisms
|
Resistant bacteria
|
Contact
|
Skin and wound if urinary tract infection in a patient with a recent
hospital or nursing home stay in a facility where multidrug-resistant
organisms
are prevalent
|
Resistant bacteria
|
Contact
|
Skin and wound infection
|
|
|
Abscess or draining wound that cannot be covered
|
Staphylococcus aureus, Group A streptococcus
|
Contact
|
* Infection control professionals are encouraged to modify or adapt this table according to local conditions. To ensure that appropriate empiric precautions are always implemented, hospitals must have systems in place to evaluate patients routinely according to these criteria as part of their pre-admission care.
** Patients with the syndromes or conditions listed below may present atypical signs or symptoms (e.g. pertussis in neonates and adults may not have paroxysmal or severe cough). The clinician’s index of suspicion should be guided by the prevalence of specific conditions in the community, as well as clinical judgement.
*** The organisms listed under “Potential Pathogens” are not
intended to represent the complete, or even the most likely,
diagnosis, but
rather possible etiologic agents that require additional precautions beyond
Standard Precautions until they can be
ruled out.
SYNOPSIS OF TYPES OF PRECAUTIONS AND PATIENTS REQUIRING THE PRECAUTIONS
Abbreviations used in list of precautions—
α See Table I for a complete list of infections requiring precautions, including appropriate footnotes.
ß Certain infections require more than one type of precaution.
Г See “Guidelines for Preventing the Transmission of Tuberculosis
in Health-Care Facilities” available from the
Department of
Health.
- Standard Precautions
Use Standard Precautions for the care of all patients.
- Airborne Precautions
In addition to Standard Precautions, use Airborne Precautions for patients
known or suspected to have serious illnesses transmitted
by the airborne droplet
nuclei. Examples of such illnesses include—
Measles
Varicella (including disseminated zoster) ß
TuberculosisГ
- Droplet Precautions
In addition to Standard Precautions, use Droplet Precautions for patients known or suspected to have illnesses transmitted by large-particle droplet.
Examples of such illnesses include—
➢ Invasive Haemophilus influenzae Type B disease, including meningitis, pneumonia, epiglottitis and sepsis;
➢ Invasive Neisseria meningitidis disease, including meningitis, pneumonia and sepsis.
Other serious bacterial respiratory infections spread by droplet
transmission, including—
- Diphtheria (pharyngeal);
- Mycoplasma pneumonia;
- Pertussis;
- Pneumonic plague;
- Streptococcal pharyngitis, pneumonia or scarlet fever in infants and young children.
Serious viral infections spread by droplet transmission,
including—
➢ Adenovirusß;
➢ Influenza;
➢ Mumps;
➢ Parvovirus B12;
➢ Rubella.
- Contact Precautions
In addition to Standard Precautions, use Contact Precautions for patients
known or suspected to have serious illnesses easily transmitted
by direct
contact or by contact with items in the patient’s environment. Examples of
such illnesses include—
- Gastrointestinal, respiratory, skin or wound infections or colonisation with multidrugresistant bacteria judged by the infection control program, based on current state, regional, or national recommendations, to be of special clinical and epidemiologic significance.
- Enteric infections with a low infectious dose or prolonged environmental survival, including—
➢ Clostridium difficile.
- For diapered or incontinent patients: enterohaemorrhagic Escherichia coli 0157: H7, Shigella, Hepatitis A or Rotavirus.
- Respiratory syncytial virus, parainfluenza virus or enteroviral infections
in infants and young children.
Skin infections that are highly contagious or that may occur on dry skin,
including—
- Diphtheria (cutaneous);
- Herpes simplex virus (neonatal or mucocutaneous);
- Impetigo;
- Major (non-contained) abcesses, cellulitis or decubitus ulcers;
- Pediculosis (lice);
- Scabies;
- Staphylococcal furunculosis in infants and young children;
- Zoster (disseminated or in the immunocompromised host);
- Viral / haemorrhagic conjunctivitis Viral haemorrhagic infections (Ebola, Lassa, Marburg, Congo-Crimean) (during early non-haemorrhagic stages).
- Formidable Epidemic Disease (FED) Precautions
In addition to Standard Precautions and Contact Precautions, use FED
precautions for persons proven or suspected of having a viral
haemorrhagic
fever. Examples of such diseases are—
- Ebola Viral Haemorrhagic Fever;
- Marburg Haemorrhagic Fever;
- Congo-Crimean Haemorrhagic Fever;
- Lassa Fever.
ANNEXURE D
BIO-HAZARD SIGN
(Regulations
10(2)(f),11(4)(b) and 14(b))
ANNEXURE E
INDICATIONS CONCERNING CONTAINMENT MEASURES AND
CONTAINMENT LEVELS
(Regulations 15(2) and 16(a) and (b))
The measures contained in this Annexure shall be applied according to the
nature of the activities, the assessment of risk and the
nature of the HBA
concerned.
|
A.
|
|
B.
|
|
|
CONTAINMENT MEASURES
|
CONTAINMENT LEVELS
|
||
|
|
Level 2
|
Level 3
|
Level 4
|
1.
|
The workplace is to be separated from any other activities in the same
building
|
No
|
Recommended
|
Yes
|
2.
|
Input air and extract air in the workplace are to be and filtered using
High Efficiency Particulate Air (HEPA) Filter or likewise
|
No
|
Yes, or extract air and safe discharge of air
|
Yes, on input and extract air and safe discharge of air
|
3.
|
Access is to be restricted to authorised persons only
|
Recommended
|
Yes
|
Yes, via airlock
|
4.
|
The workplace should be sealable in order to permit disinfection
|
No
|
Recommended
|
Yes
|
5.
|
Specified disinfection procedures
|
Yes
|
Yes
|
Yes
|
6.
|
The workplace is to be maintained at an air pressure negative to
atmosphere
|
No
|
Recommended
|
Yes
|
7.
|
Efficient vector control, e.g. rodents and insects
|
Recommended
|
Yes
|
Yes
|
8.
|
Surfaces impervious to water and easy to clean
|
Yes, for bench
|
Yes, for bench and floor
|
Yes, for bench, walls, floor and ceiling
|
9.
|
Surfaces resistant to acids, alkalis, solvents, disinfectants
|
Recommended
|
Yes
|
Yes
|
10.
|
Safe storage of a biological agent
|
Yes
|
Yes
|
Yes, secure storage
|
11.
|
An observation window or alternative is to be present so that occupants can
be seen
|
Recommended
|
Recommended
|
Yes
|
12.
|
A laboratory is to contain own equipment
|
No
|
Recommended
|
Yes
|
13.
|
Infected material, including any animal, is to be handled in a safety
cabinet or isolator or other suitable container
|
Where appropriate
|
Yes, where infection is by airborne route
|
Yes
|
14.
|
Incinerator for disposal of animal carcasses
|
Recommended
|
Yes(available)
|
Yes, on site
|
ANNEXURE F
CONTAINMENT FOR INDUSTRIAL
PROCESSES
(Regulation 16 C)
Group 1 biological agents
For work with group 1
biological agents, including life-attenuated vaccines, the principles of good
occupational safety and hygiene
should be observed.
Group 2, 3 and
4 agents
It may be appropriate to select and combine containment
requirements from different categories below on the basis of a risk assessment
related to any particular process or part of a process.
|
A.
|
|
B.
|
|
||
|
CONTAINMENT MEASURES
|
CONTAINMENT LEVELS
|
||||
|
|
Level 2
|
Level 3
|
Level 4
|
||
1.
|
Viable organisms should be handled in a system, which physically separates
the process from the environment
|
Yes
|
Yes
|
Yes
|
||
2.
|
Extracted air from the closed system should be treated so as to
|
minimise release
|
prevent release
|
prevent release
|
||
3.
|
Sample collection, addition of materials to a closed system and transfer of
viable organisms to another closed system should be performed
so as to
|
minimise release
|
prevent release
|
prevent release
|
||
4.
|
Bulk culture fluids should not be removed from the closed system unless the
viable organisms have been
|
inactivated by validated means
|
inactivated by validated chemical or physical means
|
inactivated by validated chemical or physical means
|
||
5.
|
Seals should be designed as to
|
minimise release
|
prevent release
|
prevent release
|
||
6.
|
Closed systems should be located within a controlled area—
|
Optional
|
Optional
|
Yes, and purpose- built
|
||
|
(a)
|
Biohazard signs should be posted
|
Optional
|
Yes
|
Yes
|
|
|
(b)
|
Access should be restricted to nominated personnel only
|
Optional
|
Yes
|
Yes, via an airlock
|
|
|
(c)
|
Personnel should wear protective clothing
|
Yes, work clothing
|
Yes
|
A complete change
|
|
|
(d)
|
Decontamination and washing facilities should be provided for
personnel
|
Yes
|
Yes
|
Yes
|
|
|
(e)
|
Personnel should shower before leaving the controlled area
|
No
|
Optional
|
Yes
|
|
|
(f)
|
Effluent from sinks and showers should be collected and inactivated before
release
|
No
|
Optional
|
Yes
|
|
|
(g)
|
The controlled area should be adequately ventilated to minimise air
contamination
|
Optional
|
Optional
|
Yes
|
|
|
(h)
|
The controlled area should be maintained at an air pressure negative to
atmosphere
|
No
|
Optional
|
Yes
|
|
|
(i)
|
Input air and extract air to the controlled area should be HEPA
filtered
|
No
|
Optional
|
Yes
|
|
|
(j)
|
The controlled area should be designed to contain spillage of the entire
contents of the closed system
|
No
|
Optional
|
Yes
|
|
|
(k)
|
The controlled area should be sealable in order to permit fumigation
|
No
|
Optional
|
Yes
|
|
|
(l)
|
Effluent before final discharge
|
inactivated by validated means
|
inactivated by validated chemical or physical means
|
inactivated by validated chemical or physical means
|